Emergent settles Janssen COVID vaccine manufacturing dispute; receives $50M

Emergent BioSolutions Inc.

Janssen will pay Emergent $50M by July 31, 2024 under settlement agreement.
Settlement resolves all claims and arbitration related to MSA for Ad26.COV2-S vaccine.
Parties exchange broad releases covering affiliates, officers, and directors.
Ends previously disclosed arbitration between Emergent and Janssen.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.